Last reviewed · How we verify

Right-sided Staphylococcus aureus endocarditis — Treatment Landscape & Competitive Intelligence

Right-sided Staphylococcus aureus endocarditis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Right-sided Staphylococcus aureus endocarditis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cubicin Daptomycin Baxter lipopeptide antibacterial 2003-01-01
Cubicin Cubicin Clinical Alliance for Research & Education - Infectious Diseases, LLC. Outer membrane porin protein OmpD
DAPT DAPT Baxter Hlthcare Corp Outer membrane porin protein OmpD

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 1 drug in Right-sided Staphylococcus aureus endocarditis
  2. Baxter Hlthcare Corp · 1 drug in Right-sided Staphylococcus aureus endocarditis
  3. Clinical Alliance for Research & Education - Infectious Diseases, LLC. · 1 drug in Right-sided Staphylococcus aureus endocarditis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Right-sided Staphylococcus aureus endocarditis:

Cite this brief

Drug Landscape (2026). Right-sided Staphylococcus aureus endocarditis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/right-sided-staphylococcus-aureus-endocarditis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing